In this study, we aimed to reveal the mechanisms underlying the tumor-promoting effects of 3MC in RECs, with a particular focus on HIF1α/HDAC1 and RhoA, and to determine whether simvastatin can prevent these effects. Here, RHOA is linked to neoplasm.